June 19, 2019
ELI LILLY (I4V-MC-JADY)
Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients…
Read More
TRIALS STATUS
June 19, 2019
ELI LILLY (I1F-MC-RHBX)
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab…
Read More
June 19, 2019
ELI LILLY (I1F-MC-RHBY)
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment…
Read More
June 19, 2019
NOVARTIS (CQAW039A2317)
A 12-week, multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of…
Read More
June 19, 2019
AURINIA (AUR-VCS_2016-01)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg…
Read More
June 19, 2019
NOVARTIS (CQAW039A2315)
A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when…
Read More
June 19, 2019
ENANTA PHARMACEUTICALS, INC. (EDP-305)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability,…
Read More
June 19, 2019
AURINIA (AUR-VCS_2016-02)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg…
Read More
June 19, 2019
ELI LILLY (I4V-MC-JAJA)
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis
Read More
June 19, 2019
ELI LILLY (I8F-MC-GPGH)
A Randomized, Phase 3, Open-Label Trial Comparing the effect of LY3298176 versus Titrated Insulin Degludec…
Read More
June 19, 2019
INTERCEPT PHARMACEUTICALS, INC. (747-304)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of…
Read More
